司美格鲁肽对二甲双胍、华法林、阿托伐他汀和地高辛药代动力学的影响
在健康受试者中评估司美格鲁肽稳态(1.0 mg)对二甲双胍、华法林、阿托伐他汀和地高辛药代动力学的影响。结果显示各联用药物AUC比值的90%CI均在预设区间(0.80-1.25)内,华法林INR反应无临床相关变化,未发现临床显著药代或药效相互作用,提示联用无需调整剂量。
要点
- 司美格鲁肽稳态1.0 mg不显著影响二甲双胍、华法林、阿托伐他汀和地高辛的AUC。
- 各联用药AUC比值的90%CI均在预设无相互作用区间0.80-1.25内。
- 华法林INR反应无临床相关变化,联用期间安全性事件与单用司美格鲁肽相当。
核心结论
- 司美格鲁肽与二甲双胍、华法林、阿托伐他汀和地高辛联用未发现临床显著的药代或药效相互作用,提示无需调整这些药物的剂量。
研究设计与样本
- 健康受试者自身前后对照研究,比较联用药物在司美格鲁肽治疗前与稳态(1.0 mg皮下注射)时的药代动力学。
- 联用药物给药方案:二甲双胍500 mg每日两次共3.5天,华法林25 mg单次,阿托伐他汀40 mg单次,地高辛0.5 mg单次。
主要发现
- 二甲双胍、华法林、阿托伐他汀和地高辛的药代动力学未受到临床相关程度的影响。
- 所有联用药物的AUC比值(联用司美格鲁肽前与联用后)均在预设区间0.80-1.25内。
- 司美格鲁肽未对联用药物的Cmax产生相关程度的影响。
- 联用司美格鲁肽时华法林INR反应无临床相关变化。
- 司美格鲁肽治疗的不良事件多为轻中度,联用药物时的不良事件与单用司美格鲁肽相当,多为胃肠道相关。
关键数值与推荐
- 无药物相互作用判定标准:AUC比值的90%CI在预设区间0.80-1.25内。
- 司美格鲁肽稳态剂量为1.0 mg皮下注射。
临床怎么用
- 临床联用司美格鲁肽与二甲双胍、华法林、阿托伐他汀或地高辛时,基于该研究无需进行剂量调整。
- 联用华法林时仍需常规监测INR,但该研究未观察到司美格鲁肽对INR反应有临床相关影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Semaglutide is a glucagon-like peptide-1 analogue in development for the once-weekly treatment of type 2 diabetes mellitus. Its effect on the rate and extent of absorption of concomitant oral medications (metformin, warfarin, atorvastatin and digoxin) was evaluated in healthy subjects. METHODS: Subjects received metformin (500 mg twice daily for 3.5 days), warfarin (25 mg, single dose), atorvastatin (40 mg, single dose) or digoxin (0.5 mg, single dose) before and with subcutaneous semaglutide treatment at steady state (1.0 mg). Lack of drug-drug interaction was concluded if the 90% confidence intervals for the area under the plasma concentration-time curve ratio before and with semaglutide were within a pre-specified interval (0.80-1.25). RESULTS: Overall, metformin, warfarin, atorvastatin and digoxin pharmacokinetics were not affected to a clinically relevant degree with semaglutide co-administration. Estimated area under the plasma concentration-time curve ratios for all concomitant medications before and with semaglutide treatment were within the pre-specified interval. In addition, semaglutide did not affect maximum plasma concentration of concomitant medications to a relevant degree. Furthermore, no clinically relevant change in international normalised ratio response to warfarin was observed with semaglutide co-administration. Most adverse events with semaglutide treatment were mild or moderate. Adverse events with semaglutide and co-administered medication were comparable to those reported during treatment with semaglutide alone, and were mostly gastrointestinal related. CONCLUSIONS: No clinically significant pharmacokinetic or pharmacodynamic interactions were identified and no new safety issues observed with combined treatment with semaglutide. This suggests that no dose adjustments should be required when semaglutide is administered concomitantly with these medications.
引用
- Hausner H, Derving Karsbøl J, Holst AG, et al. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clin Pharmacokinet. 2017. PMID: 28349387. doi:10.1007/s40262-017-0532-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。